BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the Company's Annual General Meeting held today, including the election of three new directors to the Company's Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have been published. The trial was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The primary objectives of the trial were to assess safety and T-cell responses to M‑001. The data, which are consistent with results of previous clinical trials of M-001, indicate that both primary objectives were achieved. Analysis of the data is ongoing, and the clinical study report (CSR) is expected in Q2 2020.

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Second Cohort of Phase 3 Trial Fully Enrolled On November 18, 2019, BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) announced that the second cohort of the Phase 3 trial of the company’s universal influenza vaccine candidate, M-001, was fully enrolled. A total of 12,463 adults aged 50 years and older have been

JERUSALEM, June 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that a patent covering production processes of the Company's M-001 universal influenza vaccine candidate was allowed in the USA and Japan. Titled "Compositions of multimeric-multiepitope influenza polypeptides and their production" the patent, which is pending in Europe, covers the unique composition and manufacturing processes of M-001. Designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza, the vaccine has been shown to be safe, well-tolerated, and immunogenic to a broad range of flu strains in clinical trials.

JERUSALEM, Israel, July 16, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) is proud to announce today the results of its previously announced rights offering. The Company has received subscriptions from existing shareholders for all the offered American Depositary Shares ("ADSs") and ordinary shares, being a total of 3,057,466 ADSs and 18,298,898 ordinary shares, raising total gross proceeds of US$20 Million.

JERUSALEM, Oct. 7, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine candidate, announced today the receipt of €4 million from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "This past June we were honored to welcome EIB Vice-President Mr. Ambroise Fayolle to our manufacturing facility in Jerusalem for a signature event celebrating the extension of the EIB-BiondVax financing agreement to €24 million.

If you own shares in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) then it's worth thinking about how it contributes to...

JERUSALEM, June 26, 2019 /PRNewswire/ -- The Board of Directors and Management of BiondVax Pharmaceuticals Ltd. (BVXV), was honored to host Mr. Ambroise Fayolle, Vice-President of the European Investment Bank (EIB), during his visit to BiondVax's new mid-size commercial scale manufacturing facility in Israel.

If you want to know who really controls BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), then you'll have to look at the...

JERUSALEM , Aug. 28, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced that effective January 16, 2020, the Company will permit holders of all outstanding warrants of the Company ("Warrants") issued to investors in connection with its initial public offering on Nasdaq (the "Warrant holders") to exercise their warrants on a cashless exercise basis. Warrant holders will continue to be able to exercise their Warrants on a cash basis as well. No other terms of the Warrants are being amended.

On July 16, 2019, BiondVax Pharmaceuticals Ltd. (BVXV) announced that the previously announced rights offering was fully subscribed and the company raised gross proceeds of $20 million through the sale of 3,057,466 American Depository Shares (ADSs) and 18,298,898 ordinary shares. BiondVax’s largest shareholder, Angels Investment High Tech Ltd. (which is wholly owned by Mr. Marius Nacht), fully subscribed for the entire allotment available to them and also exercised the option to purchase 2,203,640 ADSs and 141,538 ordinary shares that were not purchased by other shareholders. Thus, Angels Investment High Tech Ltd. total investment in the rights offering was $16.67 million, and the firm is now a controlling shareholder with a holding of approximately 42% of BiondVax.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on Nasdaq under the symbol BVXVW) will expire, according to their terms, on May 15, 2020. Warrants issued to underwriters in connection with our initial public offering in the United States will expire on May 11, 2020.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since January 1, 2020 through exercises of BiondVax warrants. The publicly traded warrants, which were issued to investors in connection with BiondVax's initial public offering on Nasdaq in 2015, had an exercise price of $6.25, traded on Nasdaq under the symbol BVXVW, and expired May 15, 2020. Warrants issued to underwriters in connection with the initial public offering expired May 11, 2020.

BiondVax Pharmaceuticals Ltd. (BVXV) secured a grant from the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, to build a manufacturing facility for the production of Phase 3 and commercial batches of its universal flu vaccine, M-001. Influenza viruses often undergo changes to certain surface proteins which results in development of new virus strains that are unfamiliar to the human body immune system. The bigger the surface protein change, the lower the possibility of body’s immune system to fight against the disease.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended September 30, 2019.

JERUSALEM, July 8, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate frequently and unpredictably, and the strains that dominate often vary in time and place. For example, according to the CDC, the first part of the 2018/19 flu season was dominated by H1 strains throughout most of the continental USA, while the south-east USA was dominated by an H3 strain.

JERUSALEM, Nov. 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal influenza vaccine candidate is complete. BiondVax's M-001 universal flu vaccine candidate is designed as a common denominator to influenza A and B viruses. Results from six completed human clinical trials indicate that M‑001 is safe, well-tolerated, and induces an immune response to a broad range of influenza strains.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in Europe of the Company's M-001 universal influenza vaccine candidate.

With the company set to enter the second enrollment season for the ongoing Phase 3 clinical trial of its universal influenza vaccine M-001, a rights offering has recently been initiated in which the company is looking to raise approximately $20 million. The terms of the rights offering allow for each shareholder and American Depositary Share (ADS) holder to receive approximately 0.54 subscription rights for each 1 ADS or share owned. In exchange, Angels Investment asked that its affiliate, aMoon2 Fund Limited Partnership, be given the option to purchase any units offered but not purchased by other shareholders, but not less than $10 million combined between Angels Investment and aMoon2.